| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 82.2 | 64.2 | 75.6 |
| Other income | 2.8 | 3.2 | 2.8 |
| Total income | 85.1 | 67.4 | 78.4 |
| Profit before exceptional items & tax | 17.7 | 11.8 | 14.4 |
| Profit before tax | 17.7 | 11.8 | 14.4 |
| Net profit | 13.2 | 8.8 | 10.8 |
| Operating margin | 20.8% | 17.5% | 18.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +22.20% |
|---|---|
| Net profit, quarter on quarter | +50.00% |
| Revenue, year on year | +8.70% |
| Operating profit, year on year | +30.00% |
| Operating profit, quarter on quarter | +85.70% |
BSE results filing, NSE: JAGSNPHARM. Figures extracted from the filing.
Jagsonpal Pharmaceuticals Ltd: key numbers
- Share price
- ₹236.58
- Market cap
- ₹1,560 Cr
- Revenue (annual)
- ₹287.2 Cr
- Net profit (annual)
- ₹43.08 Cr
- P/E (TTM)
- 34.3×Sector 47.4×
- Promoter holding
- 69.05%+1.16% QoQ
- FII holding
- 2.30%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jagsonpal Pharmaceuticals Ltd
All →Jagsonpal Pharmaceuticals Acquisition Worth ₹46.7 Cr
Jagsonpal Pharmaceuticals Ltd will acquire the Wellness Portfolio of Group Pharmaceuticals Ltd. The transaction involves a total consideration capped at ₹46.7 Crore.
- Value
- ₹46.70 Cr
Jagsonpal Pharmaceuticals Annual General Meeting
Jagsonpal Pharmaceuticals held its 47th Annual General Meeting on September 18, 2026. Shareholders transacted business including adoption of financial statements and director appointments.
Jagsonpal Pharmaceuticals Business Update
Jagsonpal Pharmaceuticals Ltd has filed its Business Responsibility and Sustainability Report for the financial year 2025-26. This report forms part of its annual report.
Jagsonpal Pharmaceuticals Annual General Meeting
Jagsonpal Pharmaceuticals Ltd has issued the notice for its 47th Annual General Meeting, scheduled for September 18, 2026, alongside the Annual Report for FY 2025-26.
Jagsonpal Pharmaceuticals Other Announcement
The company informed shareholders without registered email addresses of the web-link to access the 2025-26 Annual Report and AGM Notice, per Regulation 36(1)(b).
Jagsonpal Pharmaceuticals Employee Stock Options
Jagsonpal Pharmaceuticals Limited allotted 27,950 equity shares following the exercise of employee stock options. This increases the company's total paid-up share capital to Rs. 13.19 Crore.